Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

Features and development of Coot

Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915

Overview of the CCP 4 suite and current developments

Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950

How good are my data and what is the resolution?

Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,713

Genetic screens in human cells using the CRISPR-Cas9 system

Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856

Data processing and analysis with the autoPROC toolbox

Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O. S., Paciorek, W. A., Womack, T. O., & Bricogne, G. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911007773 · Cited by 2,084

An introduction to data reduction: space-group determination, scaling and intensity statistics

Evans, P. R. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s090744491003982x · Cited by 1,507

MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells

Kryukov, G. V., Wilson, F. H., Ruth, J. R., Paulk, J., Tsherniak, A., Marlow, S. E., Vazquez, F., Weir, B. A., Fitzgerald, M. E., Tanaka, M., et al. (2016) · Science · doi:10.1126/science.aad5214 · Cited by 688

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Chan-Penebre, E., Kuplast, K. G., Majer, C. R., Boriack-Sjodin, P. A., Wigle, T. J., Johnston, L. D., Rioux, N., Munchhof, M. J., Jin, L., Jacques, S. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1810 · Cited by 569

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J., Li, M., Fan, H. X., Lin, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210371110 · Cited by 557

Discovery of Oxime Ether Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer

Cheng, X., Hu, Z., Mao, H., Li, Z., Wang, Z., Tang, Y., Huang, S., Huang, Y., Yin, C., Xing, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02570 · Cited by 5

The Diagnostic and Prognostic Role of Combined p16 and MTAP Immunohistochemistry in Melanocytic Tumors of Uncertain Malignant Potential: A Comprehensive Review and Clinical Practice Analysis

Pepe, L. R., Fiorentino, V., Pizzimenti, C., Martini, M., Santarpía, M., Fazio, A., Vaccaro, M., Lentini, M., & Ieni, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020971 · Cited by 4

Context-dependent synthetic lethality — an emerging precision therapeutic approach

Chang, L., Shaw, K. L., Vázquez, F., & Sellers, W. R. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00929-9 · Cited by 7

Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition

Fogal, V., Michopoulos, F., Jarnuczak, A. F., Hamza, G. M., Harlfinger, S., Davey, P. R. J., Hulme, H., Atkinson, S. J., Gabrowski, P., Cheung, T., et al. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03771-w · Cited by 4

Integrated proteogenomic characterization of ampullary adenocarcinoma

Zhang, Q., Xu, X., Jiang, D., Wang, Y., Wang, H., Zhu, J., Tang, S., Wang, R., Zhao, S., Li, K., et al. (2025) · Cell Discovery · doi:10.1038/s41421-024-00742-4 · Cited by 5

Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility

Shah, P. A., Wiman, K. G., Cichowski, K. M., & Rodon, J. A. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473616 · Cited by 4

Discovery of Novel PRMT5 Inhibitors Bearing a Methylpiperazinyl Moiety

Bai, X., Zhai, Z., Zhao, X., Li, R., Liang, L., Jin, Y., & Yin, Y. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0244 · Cited by 4

The Structural Effects of Phosphorylation of Protein Arginine Methyltransferase 5 on Its Binding to Histone H4

Börzsei, R., Bayarsaikhan, B., Zsidó, B. Z., Lontay, B., & Hetényi, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911316 · Cited by 4

Mammalian Chemical Genomics towards Identifying Targets and Elucidating Modes‐of‐Action of Bioactive Compounds

Matsumoto, K., & Yoshida, M. (2021) · ChemBioChem · doi:10.1002/cbic.202100561 · Cited by 4

Bourgeoning Cancer Targets

Kriplani, P. (2022) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892817666220804142633 · Cited by 4

Synthetic lethality in MTAP-deleted tumors: a promising avenue through targeted disruption of the protein methylation pathway

Bielo, L. B., & Curigliano, G. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.009 · Cited by 4

The PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicing

Fowler, C. E., O’Hearn, N. A., Salus, G. J., Singh, A., Boutz, P. L., & Lees, J. A. (2025) · iScience · doi:10.1016/j.isci.2025.112965 · Cited by 3

Cancer Dependency Map: Past and Present

Arafeh, R., Shibue, T., Vázquez, F., & Hahn, W. C. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-024239 · Cited by 3

Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities

Zahiu, T., Mihu, C. M., Boşca, A. B., Mărginean, M. V., Mocan, L. P., Lupean, R.-A., Suflețel, R. T., Mihu, C., & Melincovici, C. S. (2025) · Diagnostics · doi:10.3390/diagnostics15111323 · Cited by 4

Updates on molecular targets and clinical trials with targeted therapies for pancreatic cancer

Safyan, R. A., & Chiorean, E. G. (2025) · Surgical Oncology · doi:10.1016/j.suronc.2025.102268 · Cited by 3

CDKN2A alternations in non-small cell lung cancer: An evaluation using next-generation sequencing

Xu, F., Chang, H., Xu, Y., Yu, C., Yao, Q., Jia, L., Zhu, X., Zhou, X., & Bai, Q. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156177 · Cited by 3

Essential lncRNAs in the human transcriptome

Liang, W.-W., Mueller, S. J., Hart, S. K., Wessels, H., Méndez‐Mancilla, A., Sookdeo, A., Choi, O., Caragine, C. M., Corman, A., Lu, L., et al. (2026) · Cell Genomics · doi:10.1016/j.xgen.2026.101253 · Cited by 3

Methylthioadenosine promotes remyelination by inducing oligodendrocyte differentiation

Moreno, B., Vila, G., Fernández-Díez, B., Vázquez, R., di Penta, A., Errea, O., Escala, N., Miguez, A., Alberch, J., & Villoslada, P. (2017) · Multiple Sclerosis and Demyelinating Disorders · doi:10.1186/s40893-017-0020-8 · Cited by 3

Pre-operative dual-time-point [18F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study

Lee, D. Y., Oh, J. S., Kim, J. W., Oh, S. J., Oh, S. J., Lee, S., Kim, J. H., Kim, J. H., Nam, S. J., Song, S. W., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06935-z · Cited by 3

Inhibitory Effect of PRMT5/ MTA Inhibitor on MTAP ‐Deficient Glioma May Be Influenced by Surrounding Normal Cells

Wang, Y., Sun, X., Ma, R., Zhang, X., Ji, S., Liu, Z., Yang, G., Wang, H., Zhang, P., Zhang, J., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70526 · Cited by 4

Discovery and Mechanism of 16–19F, a Novel Synthetic Lethal Inhibitor of the PRMT5•MTA Complex in MTAP-Deleted Cancer Cells

Shen, Z., Yang, X. T., Seabra, G. D. M., Xu, X., Dong, J., Brant, J. O., Zhou, W., Guan, J., Jiang, W., & Li, C. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00160 · Cited by 3

Common co-deletion isn't a silent passenger

Shipman, L. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.26 · Cited by 3

Targeted Therapy in Mesotheliomas: Uphill All the Way

Bertoli, E., Carlo, E. D., Bortolot, M., Stanzione, B., Conte, A. D., Spina, M., & Bearz, A. (2024) · Cancers · doi:10.3390/cancers16111971 · Cited by 3

New Drugs for Recurrent or Metastatic Nasopharyngeal Cancer

Ayodele, O., & Siu, L. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-63234-2_23 · Cited by 3

Histone methylation modifiers in medical therapeutics

Trojer, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00020-7 · Cited by 3

Genetic dependencies associated with transcription factor activities in human cancer cell lines

Thatikonda, V., Supper, V., Wachter, J., Kaya, O., Kombara, A., Bilgilier, C., Ravichandran, M. C., Lipp, J., Sharma, R., Badertscher, L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114175 · Cited by 3

Therapeutic Targeting of Methylthioadenosine Phosphorylase

(2016) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1322 · Cited by 3

Remember why we work on cancer

Garraway, L. A. (2017) · Nature · doi:10.1038/543613a · Cited by 3

Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP

Li, M., Shah, M. V., Binder, M., Lasho, T. L., Carr, R. M., Mangaonkar, A. A., Gangat, N., Coltro, G., Tefferi, A., Dao, L. N., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25675 · Cited by 3

Functional genomic analysis of adult and pediatric brain tumor isolatesPreprint

Hoellerbauer, P., Biery, M. C., Arora, S., Rao, Y., Girard, E. J., Mitchell, K., Dighe, P. A., Kufeld, M., Kuppers, D. A., Herman, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.05.522885 · Cited by 3

Discovery of Novel MTA-Cooperative PRMT5 Inhibitors with a 2,3-Dihydro-1H-imidazo[1,2-b]pyrazole Scaffold

Yang, Y., Chen, Z., Wang, Y., Huang, X., Hu, C., Yang, H. J., & Li, Y. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00185 · Cited by 2

LncRNA EP300-AS1 interacts with PTBP1 to destabilize PRMT5 mRNA and suppresses NSCLC growth and metastasis

Chen, J., Fan, C., Song, S., & Zhang, D. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07931-3 · Cited by 2

Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics

Farooq, M., & Pishvaian, M. J. (2025) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2025.08.004 · Cited by 2

Chromatin Regulatory Targets for Anticancer Therapeutics

Barta, P. A., Carter, T. R., & Erb, M. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00231 · Cited by 2

Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancer

Zhang, H., Tonini, M. R., Martires, L. C. M., Jenkins, H. N., Pratt, C. B., Gordon, E. N., Zhao, S.-C., Choi, A. H., Meier, S. R., Khendu, T., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.120070 · Cited by 2

Development of a Manufacturing Route toward AMG 193, an MTA-Cooperative PRMT5 Inhibitor

Arunachalampillai, A., Chandrappa, P., Crockett, R. D., Gaines, C. S., Hu, K., Judd, T. C., Kommuri, V. C., Murray, J. I., Nidhiry, J., Ortiz, A., et al. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00310 · Cited by 2

Immune suppression in MTAP-deficient cancers via glutamate metabolism and CXCL10 downregulation

Chang, W.-H., Zhang, J., Hong, Q., & Chen, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1634342 · Cited by 5

Furo[2,3- f ]quinazolin-7(6 H )-one Derivatives as Potent, Selective, and Orally Bioavailable MAT2A Inhibitors for MTAP-Deficient Cancer Therapy

Shi, Z., Lin, K., Lin, L., Chen, Z., Xie, Z., Sun, Y., Cui, R., Zhang, S., Zheng, M., & Xu, S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02062 · Cited by 2

Discovery of novel selective PRMT5-MTA inhibitors through structure-based virtual screening

Ma, N., Chen, Y., Liang, Y., Chen, X., Song, F., Su, Z., Wang, Y., Zhou, J., Niu, B., Hao, Y., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109363 · Cited by 2

MTAP in small biopsy samples of pancreatic lesions: a potential diagnostic biomarker. Immunohistochemical, fluorescence in situ hybridization and molecular analysis

Lucà, S., Salzillo, C., Masola, V., Vita, F. D., Porpora, D., Conzo, G., Savarese, G., Sirica, R., Cozzolino, I., Clery, E., et al. (2025) · Pathologica · doi:10.32074/1591-951x-1243 · Cited by 2

Progress in targeting the untouchables: emerging approaches for hard-to-drug cancer targets

Coleman, N., Tan, H., & Rodon, J. A. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.01.012 · Cited by 2

Genomic Landscape and Clinical Implications of MTAP Loss in Advanced Gastrointestinal Malignancies

Min-Ho, L., & Jin-Woo, C. (2024) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/1wge2vwbfg · Cited by 2

Journey of Methionine Adenosyltransferase 2A Inhibitors: From Bench to Advanced Clinical Trials

Faridoon, F., & Zhang, G. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02185 · Cited by 2

The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and Programmed Death-Ligand 1 Expression on Overall Survival in a Select Cohort From the International Association for the Study of Lung Cancer Ninth Edition Staging Database

Yang, S., Tjota, M. Y., Goren, E., Giroux, D. J., Galateau-Sallé, F., Husain, A. N., Kindler, H. L., Drazer, M. W., Aly, R. G., Dycoco, J., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103681 · Cited by 2

Rational-guided design and optimization of 6-fluoro-4-(trifluoromethyl)benzofuran-based thiazole derivatives as potent methionine adenosyltransferase 2A inhibitors: In vitro and In silico approaches

Al‐Joufi, F. A., Sarfraz, H., Khan, Y., Chohan, T. A., Alwaili, M. A., Al‐Hoshani, N., Sagini, H. A., Mansouri, O. A., Hassan, F., & Hussain, R. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.145958 · Cited by 2

Chlorella pyrenoidosa improves meat quality and flavor precursors of fattening lambs by regulating jejunal microbiota and muscle metabolism via the gut–muscle axis

Zhao, J., Li, S., Wang, J., Zeng, W., Qi, Y., Xu, X., Fan, J., Chen, C., & Zhang, W. (2026) · Food Chemistry X · doi:10.1016/j.fochx.2026.103829 · Cited by 2

The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP -Deleted Cancers

Cottrell, K. M., Briggs, K. J., Tsai, A., Liang, C., McCarren, P. R., Whittington, D. A., Zhang, M., Zhang, W., Huang, A., Andersen, J. N., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00035 · Cited by 2

Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation

Smith, J. M., Barlaam, B. C., Beattie, D., Bradshaw, L., Chan, H. M., Cooke, S. L., Cronin, A. S., Cumming, I., Dean, E. J., Debreczeni, J. E., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00659 · Cited by 2

O-mannosylation and protein maturation checkpoints represent therapeutic opportunities in BRAF fusion protein oncogenesis

Borgenvik, A., Misek, S. A., Christen, D., Kyrila, G., Zhang, A., Reel, S. M., Boisvert, M., Cai, K. X., Kovarzin, A., Li, H., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1114 · Cited by 2

The structural basis of histone modifying enzyme specificity and promiscuity: Implications for metabolic regulation and drug design

Kamerzell, T. J., Mikell, B., Chen, L., Elias, H. K., Dawn, B., MacRae, C. A., & Middaugh, C. R. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.02.004 · Cited by 2

ReACT (redox-activated chemical tagging) chemistry enables direct derivatization and fluorescence detection of S -adenosyl- l -homocysteine (SAH)

Lin, B., Xiang, L., Yuan, Z., Hou, Q., Ruan, Y., & Zhang, J. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d3ob01073b · Cited by 2

One stone two birds: Introducing piperazine into a series of nucleoside derivatives as potent and selective PRMT5 inhibitors

Li, H., Yang, H. J., Liu, L., Zheng, J., Shi, Q., Li, B., Wang, X., Zhang, Y., Zhou, R., Zhang, J., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116970 · Cited by 2

Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia

Depies, O. M., Guo, Q., Gao, Y., Sinha, S., Ye, Z., Han, W., Rabe, K. G., Hoel, M. S., Darby, H. C., Yu, C., et al. (2024) · Blood Neoplasia · doi:10.1016/j.bneo.2024.100059 · Cited by 2

Emerging Therapeutic Targets in Pancreatic Adenocarcinoma

Choe, J. H., & Abbruzzese, J. L. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_92-1 · Cited by 2

Emerging Therapeutic Targets in Pancreatic Adenocarcinoma

Choe, J. H., & Abbruzzese, J. L. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_92 · Cited by 2

Targeted Therapies for Pancreatic Cancer

Lee, M. S., & Pant, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-38623-7_5 · Cited by 2

Structural Biology of Epigenetic Targets: Exploiting Complexity

Marek, M., Shaik, T. B., & Romier, C. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527809257.ch2 · Cited by 2

Protein arginine methyltransferase 5 promotes metastasis via enhancing EGFR transcription and modulating AKT1 activation by methylationPreprint

Huang, L., Zhang, X.-O., Verdejo‐Torres, O., Wigglesworth, K., Sun, X., Sallis, B., Moon, D., Huang, T., Rozen, E. J., Wang, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.12.246660 · Cited by 2

Abemaciclib for malignant pleural mesothelioma – Authors' reply

Fennell, D. A., & Nusrat, N. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00285-6 · Cited by 2

MTAP IHC on the Map: Toward a New Predictive Biomarker in NSCLC

Mino-Kenudson, M. A., & Wang, C. I. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.09.1759 · Cited by 2

Inhibiting Arginine Methylation

Sbardella, G., & Bedford, M. T. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00343 · Cited by 1

Discovery of MTA-cooperative PRMT5 Inhibitors

Maxwell, J. P., Cottrell, K. M., & Briggs, K. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00623 · Cited by 1

Development of a Commercial Ready Process for TNG908: A Potent, Selective, and Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor

Liang, J., Li, H., Cottrell, K. M., Liu, Y., Maxwell, J. P., Xin, Z., Anzalone, L., Ronn, M., & Palmieri, M. A. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00017 · Cited by 1

Prevalence and molecular landscape of NRG1 fusions in Japanese solid tumors: a nationwide data analysis using the C-CAT database

Ishida, M., Yamada, T., Tsunashima, R., Morita, M., Kataoka, N., Kunimatsu, Y., Sawada, R., Hata, T., Kawachi, H., Iwasaku, M., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108843 · Cited by 1

Targeting methionine-induced pyroptosis enhances anti-tumor immunity

Lei, M., Zhu, W., Wang, C., Zhang, F., Li, M., Zhang, Y., Qu, J., Luo, Z., Li, J., Li, Z.-X., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3149-4 · Cited by 1

Protein Methylation as a Regulatory Logic Layer in Cancer Signaling: Interplay with Phosphorylation and Network Plasticity

Kim, K.-H., & Yoo, B. C. (2026) · Cancers · doi:10.3390/cancers18060903 · Cited by 1

A synergistic interaction between PRMT5 and LSD1 inhibitors in AML

Param, N. J., Arceci, E., Fiorentino, F., Pignata, L., Torre, D., Gutiérrez, N., Fong, J. Y., Goy, P.-A. V., Han, Y., Lambona, C., et al. (2026) · Science Advances · doi:10.1126/sciadv.aea4059 · Cited by 1

Clinicogenomic Landscape of MTAP -Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations

Ikushima, H., Watanabe, K., Shinozaki-Ushiku, A., Oda, K., & Kage, H. (2026) · JCO Precision Oncology · doi:10.1200/po-26-00100 · Cited by 2

LKB1 inactivation elicits an NNMT-mediated methyl sink and confers dependence on PRMT5 in lung cancer

Mi, W., Xia, X., Xue, Y., Li, L., Yang, L., Yang, X., Xu, J., Cai, X., Zhou, Y., Zhu, L., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117487 · Cited by 1

Exploring Privileged Structure Repurposing: Target Similarity as a Catalyst for Cross-Species Drug Discovery

Du, S., Tang, K., Li, J., Hu, X., & Zhan, P. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01234 · Cited by 1

Clinical characteristics and therapeutic implications of MTAP deletion in pancreatic cancer: A nationwide genomic analysis

Matsumoto, H., Mizuno, K., Kondo, C., Kawashima, H., Hibi, H., & Ando, Y. (2026) · Pancreatology · doi:10.1016/j.pan.2026.07.015 · Cited by 1

MTAP loss in non–small-cell lung Cancer and beyond: Therapeutic targeting of the MAT2A–PRMT5 axis

Arter, Z., Shim, J. S. G., Park, C., Waliany, S., Lim, S. M., & Soo, R. A. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103204 · Cited by 1

5′- S -(3-Aminophenyl)-5′-thioadenosine, a Novel Chemoprotective Agent for Reducing Toxic Side Effects of Fluorouracil in Treatment of MTAP-Deficient Cancers

Zhang, S., Xue, H., Wong, N. K. Y., Doerksen, T. A., Ban, F., Anderson, S. A., Volik, S. V., Lin, Y., Dai, Z., Bratanovic, I., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0656 · Cited by 1

Exploiting Synthetic Lethality of PRMT5 for Precision Treatment of MTAP-Deficient Glioblastoma

Nguyen, T. T. T., Yi, E. S., & Badr, C. E. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5030027 · Cited by 1

Protein arginine methyltransferase 5 sustains Tip60-EP400 complex via SRSF1 in Merkel cell carcinoma

Sevigny, J. L., Proctor, E. V., Adams, H., MacDonald, E. R., Thomas, W. K., & Cheng, J. (2025) · Life Science Alliance · doi:10.26508/lsa.202503316 · Cited by 2

Impact of Chromosomal Instability and Aneuploidy in Cancer Development

Mennie, A. K., Dhital, B., & Ly, P. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-071124-101613 · Cited by 3

Recent Advances in Targeted Therapies for Adult Gliomas

Lasica, A. B., Tang, A. R., Iqbal, A., Nakhate, V., & Wen, P. Y. (2026) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-026-01484-4 · Cited by 2

TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD- Deleted Cancers

Nicholson, H. E., Whittington, D. A., Bruzzese, F. J., Lazarides, K., Martires, L. C. M., Tonini, M. R., Jenkins, H. N., Zhang, M., Shahagadkar, P., Pratt, C. B., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-26-0040 · Cited by 2

Whole genome sequencing in oesophageal adenocarcinoma unmasks potential precision therapies

Sharma, S., Wong, H. Y., Johnston, R. L., Koufariotis, L. T., Wood, S., Hollway, G. E., Aoude, L. G., Davidson, A. L., Pearson, J. V., Lin, F. P., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-16044-9 · Cited by 1

MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy

Ikushima, H., & Kage, H. (2026) · Cancer Science · doi:10.1111/cas.70429 · Cited by 1

Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens

Fenoglio, S., Yu, Y., Tepper, J., Grove, L., Bejnood, A., Meier, S. R., Choi, A. H., Wu, H., Devault, A., Liu, S., et al. (2026) · Cell Reports Methods · doi:10.1016/j.crmeth.2026.101470 · Cited by 1

Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives

Ibrahim, R., Vibert, J., Moussa, T., Duong-Ngo, C., Faron, M., Verret, B., Zanella, C., Mikhael, R., Tabet, E. I., Lévy, A., et al. (2026) · Current Treatment Options in Oncology · doi:10.1007/s11864-026-01407-y · Cited by 1

The role of lipoylation in mitochondrial adaptation to methionine restriction

Xue, J., & Ye, C. (2024) · BioEssays · doi:10.1002/bies.202300218 · Cited by 1

Recent Developments in the Structural Mechanism of Protein Methyltransferase Inhibition

Leung, R., & Schapira, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00084 · Cited by 1

Histone Methylation Modifiers in Medical Therapeutics

Trojer, P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00037-5 · Cited by 1

Taking Advantage of the Collateral Damage of Cancer-Causing Mutations: MTAP Deletions Sensitize Cancer Cells to PRMT5 Inhibition

Taylor, J., & Abdel-Wahab, O. I. (2016) · The Hematologist · doi:10.1182/hem.v13.3.5375 · Cited by 1

Actitud de los odontológos generales de Murcia en relación con la biopsia oral

López‐Jornet, P., Nicolás, A. P. V., Beneyto, Y. M., & Soria, M. F. (2007) · Medicina oral, patología oral y cirugía bucal · Cited by 1

PRMT Inhibitors

van Haren, M. J., & Martin, N. I. (2019) · Topics in medicinal chemistry · doi:10.1007/7355_2019_73 · Cited by 1

Identification of Genes under Purifying Selection in Human CancersPreprint

Mathis, R. A., Sokol, E. S., & Gupta, P. B. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/129205 · Cited by 1

A common genetic architecture enables the lossy compression of large CRISPR librariesPreprint

Zhao, B., Rao, Y., Gilbert, L. A., & Pritchard, J. R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.18.423506 · Cited by 1

Molecular Understanding of the Development of Ductal Pancreatic Cancer

Lee, J. W., Hruban, R. H., & Wood, L. D. (2023) · Wiley eBooks · doi:10.1002/9781119876007.ch119 · Cited by 1

Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatmentPreprint

Zhang, Y., Xu, M., Yuan, J., Hu, Z., Jiang, J., Huang, J. S., Wang, B., Shen, J., Long, M., Fan, Y., et al. (2024) · eLife · doi:10.7554/elife.99225.1 · Cited by 1

Targeting the epigenome and immune evasion: a new chapter in PRMT5 inhibition

Shah, P. A., & Rodon, J. A. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.09.014 · Cited by 1

Energy Metabolism and Epigenetics

Bultman, S. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-31143-2_87-1 · Cited by 1

Molecular Understanding of Development of Ductal Pancreatic Cancer

Wood, L. D., & Hruban, R. H. (2018) · Wiley eBooks · doi:10.1002/9781119188421.ch90

Unmet Needs and Future Outlook of Mesothelioma Management

Fennell, D. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-16884-1_23

Targeting tumor vulnerabilities associated with loss of heterozygosity

Rendo, V., Stoimenov, I., & Sjöblom, T. (2020) · Molecular & Cellular Oncology · doi:10.1080/23723556.2020.1759390

Integrated Molecular Characterization of Lung Adenocarcinoma with Implications for Immunotherapy

Gimbrone, N. T. (2019) · Digital Commons - University of South Florida (University of South Florida)

The U6 snRNA m6A Methyltransferase METTL16 Regulates MAT2A Intron Retention Through Co-Transcriptional Splicing

Pendleton, K. E. (2017)

Promising Investigational New Drugs for Mesothelioma: What Is the Next Stage of the Treatment for Advanced Mesothelioma?

Fennell, D. A. (2021) · Respiratory disease series · doi:10.1007/978-981-15-9158-7_24

Abstract LB-017: Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to marked dependence on PRMT5

Mavrakis, K. J., McDonald, E. R., Schlabach, M. R., Billy, É., Hoffman, G. R., de Weck, A., Ruddy, D. A., Venkatesan, K., McAllister, G., deBeaumont, R. S., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-lb-017 · Cited by 3

Methylthioadenosine phosphorylase deficiency in tumors: A compelling therapeutic target

Fan, N., Zhang, Y., & Zou, S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1173356 · Cited by 42

Abstract LB-307: MTAP deletions in cancer create vulnerability to a MAT2A/PRMT5/RIOK1 axis

Marks, K. M. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-lb-307

MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells

Kryukov, G. V., Wilson, F. H., Ruth, J. R., Paulk, J., Tsherniak, A., Marlow, S. E., Vazquez, F., Weir, B. A., Fitzgerald, M. E., Tanaka, M., et al. (2016) · Science · doi:10.1126/science.aad5214 · Cited by 688

544 DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy in breast cancer

Martinez-Galán, J., Delgado, J. R., Ávila, R. D. M., Torres, B. T., Núñez, M., Valdivia, J., Luque, R., Peñalver, J., Ríos-Arrabal, S., & de Almodóvar, M. R. (2010) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(10)72251-5 · Cited by 1